ZA200703697B - Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure - Google Patents
Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failureInfo
- Publication number
- ZA200703697B ZA200703697B ZA200703697A ZA200703697A ZA200703697B ZA 200703697 B ZA200703697 B ZA 200703697B ZA 200703697 A ZA200703697 A ZA 200703697A ZA 200703697 A ZA200703697 A ZA 200703697A ZA 200703697 B ZA200703697 B ZA 200703697B
- Authority
- ZA
- South Africa
- Prior art keywords
- remodeling
- ranolazone
- treatment
- combination
- heart failure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62615404P | 2004-11-09 | 2004-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200703697B true ZA200703697B (en) | 2008-09-25 |
Family
ID=35892429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200703697A ZA200703697B (en) | 2004-11-09 | 2007-05-08 | Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure |
Country Status (15)
Country | Link |
---|---|
US (2) | US20060111361A1 (xx) |
EP (1) | EP1809289A1 (xx) |
JP (1) | JP2008519770A (xx) |
KR (1) | KR20070084063A (xx) |
CN (1) | CN101072562A (xx) |
AU (1) | AU2005304421A1 (xx) |
BR (1) | BRPI0517650A (xx) |
CA (1) | CA2586840A1 (xx) |
IL (1) | IL183056A0 (xx) |
MX (1) | MX2007005367A (xx) |
NO (1) | NO20072934L (xx) |
RU (1) | RU2007121707A (xx) |
SG (1) | SG156681A1 (xx) |
WO (1) | WO2006053161A1 (xx) |
ZA (1) | ZA200703697B (xx) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2486712C (en) * | 2002-05-21 | 2012-01-03 | Cv Therapeutics, Inc. | Method of treating diabetes |
JP5522663B2 (ja) * | 2006-09-08 | 2014-06-18 | カーディオポリマーズ, インコーポレイテッド | 全体的な心臓のサイズ変更および再形成のための心筋内パターン形成 |
US20090012413A1 (en) * | 2006-09-08 | 2009-01-08 | Sabbah Hani N | Cardiac patterning for improving diastolic function |
CA2670651A1 (en) * | 2006-12-21 | 2008-07-03 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
US20080193530A1 (en) * | 2007-02-13 | 2008-08-14 | Brent Blackburn | Use of ranolazine for the treatment of non-coronary microvascular diseases |
US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
JP2010518170A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 冠微小血管疾患の処置のためのラノラジンの使用 |
EP2136780A1 (en) * | 2007-02-13 | 2009-12-30 | CV Therapeutics Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
AU2008239681B2 (en) * | 2007-04-11 | 2013-10-03 | Henry Ford Health System | Cardiac repair, resizing and reshaping using the venous system of the heart |
KR20100033490A (ko) * | 2007-05-31 | 2010-03-30 | 질레드 팔로 알토 인코포레이티드 | 상승된 뇌-형 나트륨이뇨 펩티드에 대한 라놀라진 |
US20090012103A1 (en) * | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
US20100292217A1 (en) * | 2009-05-14 | 2010-11-18 | Gilead Palo Alto, Inc. | Ranolazine for the treatment of cns disorders |
JP2011010865A (ja) | 2009-06-30 | 2011-01-20 | Ikaria Holdings Inc | 肺高血圧の臨床的または超音波心臓検査上の証拠を伴う低酸素性呼吸器不全に罹った満期産およびほぼ満期産の新生児を治療する方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69033967T2 (de) * | 1989-06-23 | 2002-12-19 | Syntex (U.S.A.) Llc, Palo Alto | Ranolazin und verwandte Piperazine zur Behandlung von Schockzuständen |
US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
US6323226B1 (en) * | 1999-10-19 | 2001-11-27 | Texas Heart Institute | Treatment of heart disease with cox-2 inhibitors |
EP2033633A3 (en) * | 2000-02-18 | 2009-07-08 | Cv Therapeutics, Inc. | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
AU2001277938A1 (en) * | 2000-07-21 | 2002-02-05 | Cv Therapeutics, Inc. | Method for treating angina |
US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
-
2005
- 2005-11-09 BR BRPI0517650-6A patent/BRPI0517650A/pt not_active IP Right Cessation
- 2005-11-09 JP JP2007540416A patent/JP2008519770A/ja not_active Withdrawn
- 2005-11-09 AU AU2005304421A patent/AU2005304421A1/en not_active Abandoned
- 2005-11-09 RU RU2007121707/14A patent/RU2007121707A/ru not_active Application Discontinuation
- 2005-11-09 KR KR1020077010435A patent/KR20070084063A/ko not_active Application Discontinuation
- 2005-11-09 SG SG200907097-0A patent/SG156681A1/en unknown
- 2005-11-09 CA CA002586840A patent/CA2586840A1/en not_active Abandoned
- 2005-11-09 US US11/271,168 patent/US20060111361A1/en not_active Abandoned
- 2005-11-09 MX MX2007005367A patent/MX2007005367A/es unknown
- 2005-11-09 CN CNA2005800380175A patent/CN101072562A/zh active Pending
- 2005-11-09 EP EP05826116A patent/EP1809289A1/en not_active Withdrawn
- 2005-11-09 WO PCT/US2005/040824 patent/WO2006053161A1/en active Application Filing
-
2007
- 2007-05-08 ZA ZA200703697A patent/ZA200703697B/xx unknown
- 2007-05-08 IL IL183056A patent/IL183056A0/en unknown
- 2007-06-08 NO NO20072934A patent/NO20072934L/no not_active Application Discontinuation
-
2009
- 2009-02-26 US US12/393,952 patent/US20090176772A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2005304421A1 (en) | 2006-05-18 |
WO2006053161A8 (en) | 2006-09-14 |
EP1809289A1 (en) | 2007-07-25 |
KR20070084063A (ko) | 2007-08-24 |
RU2007121707A (ru) | 2008-12-20 |
JP2008519770A (ja) | 2008-06-12 |
CN101072562A (zh) | 2007-11-14 |
SG156681A1 (en) | 2009-11-26 |
US20090176772A1 (en) | 2009-07-09 |
WO2006053161A1 (en) | 2006-05-18 |
NO20072934L (no) | 2007-08-08 |
MX2007005367A (es) | 2007-06-18 |
BRPI0517650A (pt) | 2008-10-14 |
IL183056A0 (en) | 2007-10-31 |
CA2586840A1 (en) | 2006-05-18 |
US20060111361A1 (en) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200703697B (en) | Use of ranolazone in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure | |
PL1912650T3 (pl) | Zastosowanie flibanseryny w leczeniu otyłości | |
EP1814628A4 (en) | MEDIUM VOLTAGE THERAPY APPLICATIONS FOR TREATMENT OF HEART DISENESS | |
PT1978947E (pt) | Derivados nitro-óxido para utilização no tratamento de distrofias musculares | |
EP1814909A4 (en) | USE OF AIMP2DX2 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
EP1711191A4 (en) | CHLORINE IN THE TREATMENT OF NEURODEEGENERATIVE DISEASES | |
EP1731113A4 (en) | MEDICAL TREATMENT KIT | |
EP1758605A4 (en) | PROUROGUANYLIN AS THERAPEUTIC AND DIAGNOSTIC AGENTS | |
EP1874800A4 (en) | DIAGNOSTIC AND THERAPEUTIC AGENTS | |
HK1137352A1 (en) | Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent | |
ZA200701193B (en) | The use of N-aryl diazaspiracyclic compounds in the treatment of addiction | |
WO2009156182A3 (de) | Uracilderivate und deren verwendung | |
SI2148667T1 (sl) | Uporaba derivatov cikloheksanheksola pri zdravljenju okularnih bolezni | |
IL179560A0 (en) | Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | |
PL2012816T3 (pl) | Zastosowanie tymozyny 1, samej lub w kombinacji z ptx3 lub gancyklowirem, do leczenia zakażenia cytomegalowirusem | |
EP1924326A4 (en) | REDUCTION OF MYOKARD DAMAGE AND INCIDENCE OF ARRHYTHMIES FROM LOSS, REDUCTION, OR INTERRUPTION OF CORONARY BLOOD FLOW | |
ZA200709542B (en) | Combination therapy in the treatment of cancer | |
EP1952833A4 (en) | CLOSED TYPE BLOOD STORAGE TANK AND EXTRACORPORAL BLOOD CIRCULATION SYSTEM USING SAID TANK | |
ZA200610297B (en) | Novel oxabispidine compounds and their use in the treatment of cardiac arrhythmias | |
GB2411834B (en) | Composition for use in the treatment of dry skin conditions | |
EP2214634A4 (en) | SKIN MOISTURIZER, PROMOTER OF BLOOD CIRCULATION, AND EXTERNAL SKIN PRODUCTS CONTAINING MOISTURIZER FOR THE SKIN AND THE PROMOTER OF BLOOD CIRCULATION | |
PL1732487T3 (pl) | Plaster medyczny do stosowania na skórę | |
PT2182954T (pt) | Utilização de ácidos nor-biliares no tratamento de arteriosclerose | |
EP1951914A4 (en) | DIAGNOSTIC AND THERAPEUTIC METHODS AND AGENTS | |
WO2007012066A3 (en) | TRUNCATED OXIDIZED THYMOSIN β4 AND DERIVATIVES THEREOF |